World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
85
Citations
47791
World Ranking
14349
National Ranking
548

Paul Baas publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Paul Baas sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 447 publications — 48th percentile

48% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Paul Baas D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Paul Baas sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 85 D-Index — 29th percentile

29% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Paul Baas is affiliated with the Antoni van Leeuwenhoek Hospital in the Netherlands. Their research primarily focuses on medicine, with significant contributions to pulmonary and respiratory medicine and oncology. They have also worked in biotechnology, immunology, and radiology, nuclear medicine, and imaging.

The scientist's research covers a range of topics including:

  • Occupational and environmental lung diseases
  • Cancer immunotherapy and biomarkers
  • Pleural and pulmonary diseases
  • Lung cancer treatments and mutations
  • Interstitial lung diseases and idiopathic pulmonary fibrosis
  • Lung cancer diagnosis and treatment
  • Cancer research and treatments

Their body of work includes numerous scientific papers published in various journals, with a particular emphasis on lung cancer and immunotherapy. Key recent papers authored or co-authored by Paul Baas include:

  • First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial, 2021, The Lancet
  • Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials, 2020, The Lancet Respiratory Medicine
  • Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC, 2021, Journal of Thoracic Oncology
  • Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1-Positive, Advanced Non-Small-Cell Lung Cancer in the KEYNOTE-010 Study, 2020, Journal of Clinical Oncology
  • First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743, 2022, Annals of Oncology

Frequent co-authors collaborating with Paul Baas include:

  • Joachim G.J.V. Aerts
  • Aaron S. Mansfield
  • Robin Cornelissen
  • Arnaud Scherpereel
  • Solange Peters

Paul Baas has contributed significantly to several publication venues, with the largest number of articles appearing in:

  • Journal of Thoracic Oncology
  • Lung Cancer
  • Annals of Oncology
  • Journal of Clinical Oncology
  • Translational Lung Cancer Research

Their work is characterized by an emphasis on clinical trials and investigations into treatments for lung cancer and pleural diseases, particularly exploring immunotherapy approaches such as nivolumab, ipilimumab, and pembrolizumab. This research aligns with their broader interests across oncology and pulmonary medicine.

Best Publications

  • Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer

    Julie Brahmer;Karen L Reckamp;Paul Baas;Lucio Crinò

  • Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

    Roy S. Herbst;Paul Baas;Dong Wan Kim;Enriqueta Felip

  • The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.

    Peter Goldstraw;Kari Chansky;John Crowley;Ramon Rami-Porta

  • Photodynamic Therapy in Oncology

    Martijn Triesscheijn;Paul Baas;Jan H. M. Schellens;Jan H. M. Schellens;Fiona A. Stewart

  • Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial

    Willemijn S. M. E. Theelen;Heike M. U. Peulen;Ferry Lalezari;Vincent van der Noort

  • First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.

    Paul Baas;Arnaud Scherpereel;Anna K Nowak;Nobukazu Fujimoto

  • The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer

    William D. Travis;Hisao Asamura;Alexander A. Bankier;Mary Beth Beasley

  • Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

    A Scherpereel;P Astoul;P Baas;T Berghmans

  • Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

    Christian Rolfo;Philip C. Mack;Giorgio V. Scagliotti;Paul Baas

  • 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

    J. Vansteenkiste;L. Crinò;C. Dooms;J. Y. Douillard

  • Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

    Suzanne Leijen;Sjaak A. Burgers;Paul Baas;Dick Pluim

  • 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer

    W.E.E. Eberhardt;D. De Ruysscher;W. Weder;C. Le Péchoux

  • Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    P. Baas;D. Fennell;K. M. Kerr;P. E. Van Schil

  • Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.

    Willemijn S.M.E. Theelen;Dawei Chen;Vivek Verma;Brian Paul Hobbs

  • Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

    Michele Carbone;Prasad S. Adusumilli;H. Richard Alexander;Paul Baas

  • Photodynamic therapy: a promising new modality for the treatment of cancer

    J.J. Schuitmaker;P. Baas;H.L.L.M. van Leengoed;F.W. van der Meulen

  • Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

    Keith M. Kerr;Lukas Bubendorf;Martin J. Edelman;Antonio Marchetti

  • A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

    George R Blumenschein;E. F. Smit;D. Planchard;D. W. Kim

  • Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.

    Armando Santoro;Mary E. O'Brien;Rolf A. Stahel;Kristiaan Nackaerts

  • 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

    B. Besse;A. Adjei;P. Baas;P. Meldgaard

Frequent Co-Authors

Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca
Solange Peters
Solange Peters University Hospital of Lausanne
Roy S. Herbst
Roy S. Herbst Yale University
Jan H.M. Schellens
Jan H.M. Schellens Utrecht University
Edward B. Garon
Edward B. Garon University of California, Los Angeles
Rolf A. Stahel
Rolf A. Stahel University of Zurich
Egbert F. Smit
Egbert F. Smit VU University Medical Center
Jos H. Beijnen
Jos H. Beijnen Utrecht University
Anna K. Nowak
Anna K. Nowak University of Western Australia
Myung-Ju Ahn
Myung-Ju Ahn Sungkyunkwan University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn't always require the traditional path. There are numerous 6 month lpn program online options for those seeking a fast-track entry into healthcare. Licensed Practical Nurse (LPN) programs are an excellent starting point, offering entry-level experience and the ability to begin working quickly.

For those interested in advanced practice roles, psych nurse practitioner programs provide the specialized training needed to work in psychiatric and mental health settings. These online programs are designed for registered nurses looking to expand their career options and make a difference in mental healthcare.

Healthcare administration is another in-demand field that supports the medical system from behind the scenes. If affordability is a key concern, consider the cheapest online healthcare administration degree programs. These degrees can be completed fully online and open doors in hospital management, policy, and beyond.

For those aiming for leadership roles, pursuing one of the cheapest mha programs online is an efficient way to enhance your qualifications. An online Master of Healthcare Administration (MHA) prepares graduates for high-level positions in healthcare organizations—without the burden of excessive tuition costs.

Best Scientists Citing Paul Baas

Trending Scientists

Recently Published Articles